Physician profile
John Morton
NPI 1588648356
$3,080.18
in general payments reported to CMS, 2019-2025
28 companies · $747 in 2025
The $747 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $37.16 · 2021: $219 · 2022: $452 · 2023: $648 · 2024: $622 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.73 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.21 | 2019-2023 | |
| Astellas Pharma US INC | $388.08 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $329.11 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $249.62 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $225.36 | 2019-2025 | |
| Myovant Sciences INC. | $209.22 | 2021-2022 | |
| Exact Sciences Corporation | $185.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $146.99 | 2022-2023 | |
| Hologic Sales and Service, LLC | $123.43 | 2019-2024 | Acessa Provu System, Aptima |
| Exeltis, USA INC. | $93.86 | 2023-2024 | Tyblume, Slynd |
| Lilly USA, LLC | $83.47 | 2025 | Mounjaro |
| Cranial Technologies, INC | $82.69 | 2023-2025 | Doc Band |
| Therapeuticsmd, INC. | $69.62 | 2021 | |
| Davol INC. | $61.33 | 2021-2024 | Arista Ah Flexitip |
| Mayne Pharma Commercial LLC | $59.03 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $46.75 | 2023-2024 | Nexplanon |
| Minerva Surgical, INC | $43.18 | 2022 | |
| Coopersurgical, INC. | $39.12 | 2024-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $38.07 | 2019-2025 | Vaxelis, Gardasil 9, Enflonsia |
| Ferring Pharmaceuticals INC. | $36.22 | 2023-2025 | Rebyota |
| Medicomp INC | $32.64 | 2024 | Telepatch Cardiac Monitor |
| Convatec INC. | $28.82 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.21 | 2025 | |
| Glaxosmithkline, LLC. | $18.77 | 2019 | |
| Supernus Pharmaceuticals, INC. | $18.62 | 2025 | Qelbree |
| Becton, Dickinson and Company | $18.43 | 2025 | Bd Onclarity |
| Dexcom, INC. | $14.49 | 2024 | Dexcom G6 Transmitter |
| Lupin INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.